• Return to Headlines

Revance Therapeu has the Lowest Debt-to-Capital Ratio in the Pharmaceuticals Industry (RVNC, COLL, AMPH, AGN, PETX)

By Shiri Gupta

Below are the three companies in the Pharmaceuticals industry with the lowest Debt-to-Capital ratios. The debt-to-capital ratio is an important measure of how a company is financing its operations along with some insight into its financial strength, relative to other companies in its industry.

Revance Therapeu ranks lowest with a a Debt-to-Capital ratio of 69.1%. Following is Collegium Pharma with a a Debt-to-Capital ratio of 140.1%. Amphastar Pharma ranks third lowest with a a Debt-to-Capital ratio of 1,226.5%.

Allergan Plc follows with a a Debt-to-Capital ratio of 2,894.3%, and Aratana Therapeu rounds out the bottom five with a a Debt-to-Capital ratio of 3,148.5%.

SmarTrend recommended that subscribers consider buying shares of Allergan Plc on June 20th, 2019 as our technology indicated a new Uptrend was in progress when shares hit $130.21. Since that recommendation, shares of Allergan Plc have risen 47.9%. We continue to monitor Allergan Plc for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: lowest debt-to-capital ratio revance therapeu collegium pharma amphastar pharma allergan plc aratana therapeu

Ticker(s): RVNC COLL AMPH AGN PETX